Compare Gilead Sciences, Inc. (GILD) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Alliant Energy Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.3 (market cap $163.51B), while Alliant Energy Corporation trades at $75.55 (market cap $19.25B). The key difference: Gilead Sciences, Inc. is far larger — about 8.5× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| GILD | LNT | |
|---|---|---|
Market Cap | $163.51B | $19.25B |
Sector | Health | Utilities |
52-Week High | $155.80 | $78.03 |
52-Week Low | $108.22 | $62.87 |
Enterprise Value | $178.05B | $30.98B |
Dividend Yield | 2.49% | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
LNT trades at $76.31, down 0.42% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $78.50. The company reported Q1 2026 EPS of $0.82, beating estimates, with revenue growth and a net income margin of 18.58%. Recent news highlights a $13.4 billion clean energy investment plan targeting 5-7% annual earnings growth, supported by rising data center demand.
The outlook for LNT is positive, driven by strategic capital investments and regulatory support for utilities. Key opportunities include earnings growth from data center expansion and renewable projects, while risks involve execution of large-scale investments and rising debt levels, with the debt-to-asset ratio increasing to 48.48% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
